Bron D
Institut Jules Bordet, Free University of Brussels, Belgium.
Curr Opin Oncol. 1994 Jul;6(4):358-64. doi: 10.1097/00001622-199407000-00006.
Combinations of drugs such as methotrexate, cyclosporin A, and prednisone have reduced the incidence of graft-versus-host disease (GVHD) to 20% to 30%. However, GVDH remains a major complication (up to 90%) following allogeneic bone marrow transplantation from unrelated or mismatched donors. GVHD is now understood as a two-step phenomenon: first, the activation of specific cytotoxic T cells and second, the release of several cytokines. Recent treatment modalities, including new immunosuppressors, T-cell depletion, and anticytokine monoclonal antibodies are discussed.
诸如甲氨蝶呤、环孢素A和泼尼松等药物联合使用已将移植物抗宿主病（GVHD）的发生率降低至20%至30%。然而，在来自不相关或不匹配供体的异基因骨髓移植后，GVHD仍然是一种主要并发症（高达90%）。现在认为GVHD是一种两步现象：首先，特定细胞毒性T细胞的激活，其次，几种细胞因子的释放。文中讨论了包括新型免疫抑制剂、T细胞清除和抗细胞因子单克隆抗体在内的最新治疗方式。
